Alerts will be sent to your verified email
Verify Email
GLAXO
|
Glaxosmithkline Phar
|
Glenmark Pharma
|
Ipca Laboratories
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
40.73 % | 3.99 % | 13.55 % |
|
5yr Avg Net Profit Margin
|
24.91 % | 2.85 % | 11.88 % |
|
Price to Book
|
24.35 | 6.15 | 4.99 |
|
P/E
|
50.0 | 72.2 | 44.5 |
|
5yr Avg Cash Conversion Cycle
|
-107.65 Days | -150.94 Days | 54.3 Days |
|
5yr Average Interest Coverage Ratio
|
479.64 | 4.25 | 50.79 |
|
5yr Avg ROCE
|
44.44 % | 17.54 % | 17.31 % |
|
5yr Avg Operating Profit Margin
|
25.23 % | 15.96 % | 19.8 % |
|
5 yr average Debt to Equity
|
0.0 | 0.38 | 0.17 |
|
5yr CAGR Net Profit
|
20.96 % | 1.54 % | -8.34 % |
|
5yr Average Return on Assets
|
21.84 % | 2.09 % | 9.41 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
75.0 % | 46.65 % | 44.72 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.0 | 0.0 | -1.57 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
1.11 % | 9.74 % | 0.2 % |
|
Glaxosmithkline Phar
|
Glenmark Pharma
|
Ipca Laboratories
|
|---|